EOLS Evolus Inc: Total Company Value-to-Revenue Ratio

evolus.com (EOLS) - corporate logo

Evolus, Inc. (EOLS) generates revenue from the sale of its high-margin Jeuveau neurotoxin for aesthetic correction. However, reliance on a single counterparty and industry price wars create risks for profitability. The company's EV/Sales multiple helps assess the risk of a drawdown, with the current level standing at 1804.19. Growing brand popularity among youth and the launch of new fillers are driving further revenue growth.

Evolus, Inc. - EOLS EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

Evolus Corp - analytical breakdowns and key metrics (EOLS)

- current quotes and average value forecast:
Fundamental valuation:EOLS (Evolus, Inc.)
Finished products of Jeuveau

This indicator compares the total enterprise value of the business to its annual revenue, excluding the impact of debt obligations. The EV/Revenue trend allows for the determination of the asset's overvaluation under inflationary pressure. A decrease in this ratio signals an increase in investment attractiveness. For Evolus, Inc. (EOLS), this parameter is critical due to the discretionary nature of demand for injections. The cyclicality of aesthetic medicine makes the valuation sensitive to economic cycles.

Competitor analysis for Evolus, Inc.

Enterprise Value-to-Revenue Multiple hcahealthcare.com|THC: EV/Sales Multiple|FMS - Total Company Value-to-Revenue Ratio|Company Value to Revenue SOLV|Encompass (EHC) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Universal Health Services, Inc. (UHS)|DaVita Inc. - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio RadNet Corp RDNT|EV/Sales Multiple Option Care OPCH|Surgery Partners Inc - EV/Sales Multiple|PINC (Premier Corp) - Company Value to Revenue Ratio|nationalvision.com (EYE) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Progyny|Company Value to Revenue ARDT|EV/Sales Multiple Select Medical Corporation|Company Value to Revenue ASTH (Astrana Health)|Company Value to Revenue Pediatrix MD|U.S. Physical Therapy - Company Value to Revenue|Business Value to Revenue PNTG|Organogenesis - EV/Sales Multiple|NUTX (Nutex Health) - Company Value to Revenue Ratio|AUNA (Auna) - Company Value to Revenue|Enterprise Value to Sales Volume SBC (SBC Medical Group Holdings)|Enterprise Value-to-Revenue Ratio chs.net|SKIN: Business Value to Revenue|EV/Sales Multiple MDWD|BTMD - Enterprise Value-to-Revenue Multiple|The Joint Chiropractic - Company Value to Revenue|Enterprise Value-to-Revenue Coefficient DCGO (DocGo, Inc)|Total Company Value-to-Revenue Ratio PIII (p3hp.org)|GANX (Gain Therapeutics) - Company Value to Revenue Ratio|euda.com (EUDA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Basel Medical|CLGN (CollPlant Biotechnologies) - EV/Sales Multiple|EV/Sales Multiple Cuprina Holdings Limited|Enterprise Value-to-Revenue Ratio concordmedical.com (CCM)|Enterprise Value-to-Revenue Ratio AMS (American Shared Hospital)|Enterprise Value-to-Revenue Ratio MEDIROM Corp MRM|EV/Sales Multiple avalon-globocare.com ALBT|DHAI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Longevity Health Holdings XAGE|NIVF (NewGenIvf Group Limited) - Company Value to Revenue|ATI Physical Therapy Inc. - Business Value to Revenue|CMAX (caremax.com) - EV/Sales Multiple|KDLY (Kindly MD Inc) - Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio ModivCare Corp (MODV)|Total Company Value-to-Revenue Ratio Novo Integrated Sciences|SunLink Health Systems, Inc. - Company Value to Revenue|imacholdings.comm (BACK) - Enterprise Value-to-Revenue Multiple